{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:15:43Z","timestamp":1790720143723,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,2]]},"DOI":"10.7759\/cureus.68438","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T10:56:56Z","timestamp":1725274616000},"source":"Crossref","is-referenced-by-count":1,"title":["Refractory Dupilumab-Induced Inflammatory Arthritis Treated by Upadacitinib: A \u2018Janus Kinase (JAK)\u2019 of All Trades"],"prefix":"10.7759","author":[{"given":"Shiamak","family":"Cooper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Ocon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2023911","article-title":"Atopic dermatitis","volume":"384","author":"St\u00e4nder S","year":"2021","unstructured":"St\u00e4nder S. Atopic dermatitis. N Engl J Med. 2021, 384:1136-1143. 10.1056\/NEJMra2023911","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Atopic dermatitis (eczema) guidelines. 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE\u2212 and Institute of Medicine\u2212based recommendations American College of Allergy, Asthma & Immunology. (2023). Accessed: July 21, 2024: https:\/\/doi.org\/10.1016\/j.anai.2023.11.009 .","DOI":"10.1016\/j.anai.2023.11.009"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18031","article-title":"Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series","volume":"181","author":"Willsmore ZN","year":"2019","unstructured":"Willsmore ZN, Woolf RT, Hughes C, Menon B, Kirkham B, Smith CH, Pink AE. Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. Br J Dermatol. 2019, 181:1068-1070. 10.1111\/bjd.18031","journal-title":"Br J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14050","article-title":"Acute arthritis and arthralgia as an adverse drug reaction to dupilumab","volume":"45","author":"de Wijs LE","year":"2020","unstructured":"de Wijs LE, van der Waa JD, de Jong PH, Hijnen DJ. Acute arthritis and arthralgia as an adverse drug reaction to dupilumab. Clin Exp Dermatol. 2020, 45:262-263. 10.1111\/ced.14050","journal-title":"Clin Exp Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14984","article-title":"Acute spondyloarthritis developing during successful treatment with dupilumab for severe atopic dermatitis","volume":"47","author":"Raimondo A","year":"2022","unstructured":"Raimondo A, Guglielmi G, Marino C, Ligrone L, Lembo S. Acute spondyloarthritis developing during successful treatment with dupilumab for severe atopic dermatitis. Clin Exp Dermatol. 2022, 47:592-593. 10.1111\/ced.14984","journal-title":"Clin Exp Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/art.42558","article-title":"Characterization of a musculoskeletal syndrome of enthesitis and arthritis in patients with atopic dermatitis treated with dupilumab, an interleukin-4\/13 inhibitor","volume":"75","author":"Hughes CD","year":"2023","unstructured":"Hughes CD, Nathan J, Mathew L, et al.. Characterization of a musculoskeletal syndrome of enthesitis and arthritis in patients with atopic dermatitis treated with dupilumab, an interleukin-4\/13 inhibitor. Arthritis Rheumatol. 2023, 75:1793-1797. 10.1002\/art.42558","journal-title":"Arthritis Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15872","article-title":"Arthritis and enthesitis during dupilumab therapy completely remitted by celecoxib","volume":"48","author":"Komaki R","year":"2021","unstructured":"Komaki R, Miyagaki T, Nakajima K, et al.. Arthritis and enthesitis during dupilumab therapy completely remitted by celecoxib. J Dermatol. 2021, 48:e279-e280. 10.1111\/1346-8138.15872","journal-title":"J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.1363","article-title":"AB0573 dupilumab-induced enthesitis\/arthritis in patients with atopic dermatitis: a retrospective observational study","volume":"80","author":"Nathan J","year":"2021","unstructured":"Nathan J, Hughes C, Patel S, et al.. AB0573 dupilumab-induced enthesitis\/arthritis in patients with atopic dermatitis: a retrospective observational study. Ann Rheum Dis. 2021, 80:1323-1324. 10.1136\/annrheumdis-2021-eular.1363","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa568","article-title":"Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy","volume":"60","author":"Bridgewood C","year":"2021","unstructured":"Bridgewood C, Sharif K, Freeston J, et al.. Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy. Rheumatology (Oxford). 2021, 60:2461-2466. 10.1093\/rheumatology\/keaa568","journal-title":"Rheumatology (Oxford)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1416922112","article-title":"IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells","volume":"112","author":"Guenova E","year":"2015","unstructured":"Guenova E, Skabytska Y, Hoetzenecker W, et al.. IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. Proc Natl Acad Sci USA. 2015, 112:2163-2168. 10.1073\/pnas.1416922112","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review","volume":"13","author":"Huang IH","year":"2022","unstructured":"Huang IH, Chung WH, Wu PC, Chen CB. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol. 2022, 13:1068260. 10.3389\/fimmu.2022.1068260","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113741","article-title":"Regulation of skin barrier function via competition between AHR axis versus IL-13\/IL-4JAKSTAT6\/STAT3 axis: Pathogenic and therapeutic implications in atopic dermatitis","volume":"9","author":"Furue M","year":"2020","unstructured":"Furue M. Regulation of skin barrier function via competition between AHR axis versus IL-13\/IL-4JAKSTAT6\/STAT3 axis: Pathogenic and therapeutic implications in atopic dermatitis. J Clin Med. 2020, 9:3741. 10.3390\/jcm9113741","journal-title":"J Clin Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-011-1036-6","article-title":"IL-17 receptor and its functional significance in psoriatic arthritis","volume":"359","author":"Raychaudhuri SP","year":"2012","unstructured":"Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012, 359:419-429. 10.1007\/s11010-011-1036-6","journal-title":"Mol Cell Biochem"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2961-7","article-title":"Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis","volume":"34","author":"Raychaudhuri SK","year":"2015","unstructured":"Raychaudhuri SK, Saxena A, Raychaudhuri SP. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheumatol. 2015, 34:1019-1023. 10.1007\/s10067-015-2961-7","journal-title":"Clin Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-211046","article-title":"Regulatory role of the JAK STAT kinase signalling system on the IL-23\/IL-17 cytokine axis in psoriatic arthritis","volume":"76","author":"Raychaudhuri SK","year":"2017","unstructured":"Raychaudhuri SK, Abria C, Raychaudhuri SP. Regulatory role of the JAK STAT kinase signalling system on the IL-23\/IL-17 cytokine axis in psoriatic arthritis. Ann Rheum Dis. 2017, 76:e36. 10.1136\/annrheumdis-2016-211046","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/290426-refractory-dupilumab-induced-inflammatory-arthritis-treated-by-upadacitinib-a-janus-kinase-jak-of-all-trades","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T10:57:06Z","timestamp":1725274626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/290426-refractory-dupilumab-induced-inflammatory-arthritis-treated-by-upadacitinib-a-janus-kinase-jak-of-all-trades"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.68438","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,2]]}}}